NASDAQ, VRTX - Vertex Pharmaceutic
We are in the business of discovering, developing and commercializing small
molecule drugs for the treatment of serious diseases. Telaprevir, our lead drug
candidate, is an oral hepatitis C protease inhibitor and one of the most
advanced of a new class of antiviral treatments in clinical development that
target hepatitis C virus, or HCV, infection, a life-threatening disease. We
expect to begin a Phase 3 clinical trial of telaprevir in March 2008 to evaluate
24-week telaprevir-based treatment regimens in treatment-na?ve patients with
genotype 1 HCV.
We have built a drug discovery capability that integrates biology,
pharmacology, biophysics, chemistry, automation and information technologies in
a coordinated manner, with the goal of more efficiently identifying promising
drug candidates to address significant unmet medical needs. ...
Read SEC Filing on NASDAQ.com »